PCPP-formulated H5N1 influenza vaccine displays improved stability and dose-sparing effect in lethal challenge studies

Journal of Pharmaceutical Sciences

Volumn 100, Issue 4, 2011, Pages 1436-1443

  Andrianov, Alexander K ^a   Decollibus, Daniel P ^a   Marin, Alexander ^a   Webb, Ashley ^b   Griffin, Yolanda ^b   Webby, Richard J ^b  

^a Apogee Technology Inc   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Biodegradable polymers vaccine delivery; Polyelectrolytes; Polymeric drug delivery systems; Stabilization; Vaccine adjuvants

Indexed keywords

IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; POLY[DI(CARBOXYLATOPHENOXY)PHOSPHAZENE]; STABILIZING AGENT; UNCLASSIFIED DRUG; EXCIPIENT; ORGANOPHOSPHORUS COMPOUND; POLY(DI(CARBOXYLATOPHENOXY)PHOSPHAZENE); POLYMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMICAL STRUCTURE; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG ANTIGENICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG STABILITY; FERRET; GEL PERMEATION CHROMATOGRAPHY; IMMUNODIFFUSION; IN VITRO STUDY; INFLUENZA A (H5N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; LETHAL DOSE; LOW DRUG DOSE; NONHUMAN; PHYSICAL CHEMISTRY; PROTECTION; THERMOSTABILITY; ANIMAL; CHEMISTRY; HUMAN; IMMUNOLOGY; ORTHOMYXOVIRIDAE INFECTIONS; VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; EXCIPIENTS; FERRETS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; ORGANOPHOSPHORUS COMPOUNDS; ORTHOMYXOVIRIDAE INFECTIONS; POLYMERS;

EID: 79951922551     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22367     Document Type: Article

References (36)

1. Poland GA. 2006. Vaccines against avian influenza-A race against time. N Engl J Med 354(13):1411-1413.
2. Poland GA, Sambhara S. 2008. Vaccines against influenza A (H5N1): Evidence of progress. J Infect Dis 198(5):629-631.
3. Subbarao K, Joseph T. 2007. Scientific barriers to developing vaccines against avian influenza viruses. Nat Rev Immuno 7(4):267-278.
4. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. 2006. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354(13):1343-1351.
5. Subbarao K, Murphy BR, Fauci AS. 2006. Development of effective vaccines against pandemic influenza. Immunity 24(1):5-9.
6. Levie K, Leroux-Roels I, Hoppenbrouwers K, Kervyn AD, Vandermeulen C, Forgus S, Leroux-Roels G, Pichon S, Kusters I. 2008. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J Infect Dis 198(5):642-649.
7. Jennings LC, Monto AS, Chan PKS, Szucs TD, Nicholson KG. 2008. Stockpiling prepandemic influenza vaccines: A new cornerstone of pandemic preparedness plans. Lancet Infect Dis 8(10):650-658.
8. World Health Organization. 2007. Informal consultation on technical specifications for a WHO international H5N1 vaccine stockpile. Final Report.Geneva, Switzerland.
9. World Health Organization. 2007. W.H.O. Expert Committee on Biological Standardization. Proposed guidelines: Regulatory preparedness for human pandemic influenza vaccines. Geneva, Switzerland.
10. Amorij JP, Huckriede A, Wilschut J, Frijlink HW, Hinrichs WLJ. 2008. Development of stable influenza vaccine powder formulations: Challenges and possibilities. Pharm Res 25(6):1256-1273.
11. Luykx D, Casteleijn MG, Jiskoot W, Westdijk J, Jongen P. 2004. Physicochemical studies on the stability of influenza haemagglutinin in vaccine bulk material. Eur J Pharm Sci 23(1):65-75.
12. Mutwiri G, Benjamin P, Soita H, Townsend H, Yost R, Roberts B, Andrianov AK, Babiuk LA. 2007. Poly[di(sodium carboxylatoethylphenoxy)phosphazene] (PCEP) is a potent enhancer of mixed Th1/Th2 immune responses in mice immunized with influenza virus antigens. Vaccine 25(7):1204-1213.
13. Payne LG, Jenkins SA, Woods AL, Grund EM, Geribo WE, Loebelenz JR, Andrianov AK, Roberts BE. 1998. Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine. Vaccine 16(1):92-98.
14. Bouveret Le Cam NN, Ronco J, Francon A, Blondeau C, Fanget B. 1998. Adjuvants for influenza vaccine. Res Immunol 149(1):19-23.
15. Kim JH, Kirsch EA, Gilliam B, Michael NL, VanCott TC, Ratto-Kim S, Cox J, Nielsen R, Robb ML, Caudrelier P, El Habib R, McNeil J. 1999. Abstracts of the 37th Annual Meeting of the Infectious Diseases Society of America. Philadelphia, Pennsylvania, pp 1028.
16. Andrianov AK. 2009. Polyphosphazene vaccine delivery vehicles: State of development and perspectives. In Polyphosphazenes for biomedical applications; Andrianov AK Ed., Hoboken, New Jersey: John Wiley & Sons, pp 47-63.
17. Andrianov AK, Marin A, Roberts BE. 2005. Polyphosphazene polyelectrolytes: A link between the formation of noncovalent complexes with antigenic proteins and immunostimulating activity. Biomacromolecules 6(3):1375-1379.
18. Andrianov AK, Le Golvan MP. 1996. Characterization of poly[di(carboxylatophenoxy)-phosphazene] by an aqueous gel permeation chromatography. J Appl Polym Sci 60(12):2289-2295.
19. Wood JM, Schild GC, Newman RW, Seagroatt V. 1977. An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: Application for potency determinations of inactivated whole virus and subunit vaccines. J Biol Stand 5(3):237-247.
20. Gill HS, Prausnitz MR. 2007. Coated microneedles for transdermal delivery. J Control Release 117(2):227-237.
21. Gill HS, Prausnitz MR. 2007. Coating formulations for microneedles. Pharm Res 24(7):1369-1380.
22. Andrianov AK, DeCollibus DP, Gillis HA, Kha HH, Marin A, Prausnitz MR, Babiuk LA, Townsend H, Mutwiri G. 2009. Poly[di(carboxylatophenoxy)phosphazene] is a potent adjuvant for intradermal immunization. Proc Natl Acad Sci U S A 106(45):18936-18941.
23. Cooper CL, Dubin PL, Kayitmazer AB, Turksen S. 2005. Polyelectrolyte-protein complexes. Curr Opin Colloid Interface Sci 10(1-2):52-78.
24. Imamura A. 1996. Charge-transfer complexation in an aqueous polyelectrolyte solution.. complexation between pyrenesulfonate or anthracenesulfonate and anthraquinonesulfonate ions. Bull Chem Soc Jpn 69:2453-2459.
25. Schild GC, Wood JM, Newman RW. 1975. A single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: Proposals for an assay method for the haemagglutinin content of influenza vaccines. Bull World Health Organ 52(2):223-231.
26. Wang W. 2000. Lyophilization and development of solid protein pharmaceuticals. Int J Pharm 203(1-2):1-60.
27. Kotz J, Kosmella S, Beitz T. 2001. Self-assembled polyelectrolyte systems. Prog Polym Sci 26(8):1199-1232.
28. Boeris V, Romanini D, Farruggia B, Picy G. 2009. Interaction and complex formation between catalase and cationic polyelectrolytes: Chitosan and Eudragit E100. Int J Biol Macromol 45(2):103-108.
29. Shalova IN, Asryants RA, Sholukh MV, Saso L, Kurganov BI, Muronetz VI, Izumrudov VA. 2005. Interaction of polyanions with basic proteins, 2 (a): Influence of complexing polyanions on the thermo-aggregation of oligomeric enzymes. Macromol Biosci 5(12):1184-1192.
30. Champeil P, Menguy T, Tribet C, Popot JL, Le Maire M. 2000. Interaction of amphipols with sarcoplasmic reticulum Ca2+-ATPase. J Biol Chem 275(25):18623-18637.
31. Picard M, Dahmane T, Garrigos M, Gauron C, Giusti F, Le Maire M, Popot J-L, Champeil P. 2006. Protective and inhibitory effects of various types of amphipols on the Ca2+-ATPase from sarcoplasmic reticulum: A comparative study. Biochemistry 45(6):1861-1869.
32. Tam KC, Wyn-Jones E. 2006. Insights on polymer surfactant complex structures during the binding of surfactants to polymers as measured by equilibrium and structural techniques. Chem Soc Rev 35(8):693-709.
33. Prausnitz MR, Mikszta JA, Cormier M, Andrianov AK. 2009. Microneedle-based vaccines. In Current topics in microbiology and immunology Vol 333: Vaccines for pandemic influenza;Compans RW, Orenstein WA, Eds. Berlin: Springer, pp 369-393.
34. Quan F-S, Kim Y-C, Yoo D-G, Compans RW, Prausnitz MR, Kang S-M. 2009. Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skin. PLoS ONE 4(9):e7152.
35. Govorkova EA, Webby RJ, Humberd J, Seiler JP, Webster RG. 2006. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J Infect Dis 194(2):159-167.
36. Baras B, Stittelaar KJ, Simon JH, Thoolen RJMM, Mossman SP, Pistoor FHM, Van Amerongen G, Wettendorff MA, Hanon E, Osterhaus ADME. 2008. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS ONE 3(1):e1401.